Ma Ya-Nan, Ma Si-Rong, Yang Li, Wu Juan, Wang Ya-Rong, Bao Li-Jia, Ma Li, Wu Qing-Qiu, Wang Zhen-Hai
Department of Geriatrics and Specialty Medicine, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China.
School of Basic Medical Sciences, Ningxia Medical University, Yinchuan, Ningxia, China.
BMC Neurol. 2025 May 8;25(1):201. doi: 10.1186/s12883-025-04212-6.
COVID-19 is a disease that affects people globally. Beyond affecting the respiratory system, COVID-19 patients are at an elevated risk for both venous and arterial thrombosis. This heightened risk contributes to an increased probability of acute complications, including acute myocardial infarction (AMI) and acute ischemic stroke (AIS). Given the unclear relationship between COVID-19, AMI, and AIS, it is crucial to gain a deeper understanding of their associations and potential molecular mechanisms. This study aims to utilize bioinformatics to analyze gene expression data, identify potential therapeutic targets and biomarkers, and explore the role of immune cells in the disease.
This study employed three Gene Expression Omnibus (GEO) datasets for analysis, which included data on COVID-19, AMI and AIS. We performed enrichment analysis on the co-DEGs for these three diseases to clarify gene pathways and functions, and also examined the relationship between co-DEGs and immune infiltration. Machine learning techniques and protein-protein interaction networks (PPI) were used to identify hub genes within the co-DEGs. Finally, we employed a dual validation strategy integrating independent GEO datasets and in vitro experiments with human blood samples to comprehensively assess the reliability of our experimental findings.
We identified 88 co-DEGs associated with COVID-19, AMI and AIS. Enrichment analysis results indicated that co-DEGs were significantly enriched in immune inflammatory responses related to leukocytes and neutrophils. Immune infiltration analysis revealed significant differences in immune cell populations between the disease group and the normal group. Finally, genes selected through machine learning methods included: CLEC4E, S100A12, and IL1R2. Based on the PPI network, the top ten most influential DEGs were identified as MMP9, TLR2, TLR4, ITGAM, S100A12, FCGR1A, CD163, FCER1G, FPR2, and CLEC4D. The integration of the protein-protein interaction (PPI) network with machine learning techniques facilitated the identification of S100A12 as a potential common biomarker for early diagnosis and a therapeutic target for all three diseases. Ultimately, validation of S100A12 showed that it was consistent with our experimental results, confirming its reliability as a biomarker. Moreover, it demonstrated good diagnostic performance for the three diseases.
We employed bioinformatics methods and machine learning to investigate common diagnostic biomarkers and immune infiltration characteristics of COVID-19, AMI and AIS. Functional and pathway analyses indicated that the co-DEGs were primarily enriched in immune inflammatory responses related to leukocytes and neutrophils. Through two machine learning approaches and the PPI network, and subsequent validation and evaluation, we identified S100A12 as a potential common therapeutic target and biomarker related to immune response that may influence these three diseases.
新型冠状病毒肺炎(COVID-19)是一种全球范围内影响人类的疾病。除了影响呼吸系统外,COVID-19患者发生静脉和动脉血栓形成的风险也有所升高。这种风险的增加导致急性并发症(包括急性心肌梗死(AMI)和急性缺血性卒中(AIS))的发生概率增加。鉴于COVID-19、AMI和AIS之间的关系尚不清楚,深入了解它们之间的关联及潜在分子机制至关重要。本研究旨在利用生物信息学分析基因表达数据,识别潜在的治疗靶点和生物标志物,并探讨免疫细胞在该疾病中的作用。
本研究采用了三个基因表达综合数据库(GEO)数据集进行分析,其中包括COVID-19、AMI和AIS的数据。我们对这三种疾病的共同差异表达基因(co-DEGs)进行了富集分析,以阐明基因途径和功能,并研究了co-DEGs与免疫浸润之间的关系。利用机器学习技术和蛋白质-蛋白质相互作用网络(PPI)来识别co-DEGs中的核心基因。最后,我们采用了一种双重验证策略,将独立的GEO数据集与针对人类血液样本的体外实验相结合,以全面评估我们实验结果的可靠性。
我们识别出88个与COVID-19、AMI和AIS相关的共同差异表达基因。富集分析结果表明,co-DEGs在与白细胞和中性粒细胞相关的免疫炎症反应中显著富集。免疫浸润分析显示,疾病组和正常组之间的免疫细胞群体存在显著差异。最后,通过机器学习方法筛选出的基因包括:CLEC4E、S100A12和IL1R2。基于PPI网络,确定了十大最具影响力的差异表达基因,分别为MMP9、TLR2、TLR4、ITGAM、S100A12、FCGR1A、CD163、FCER1G、FPR2和CLEC4D。蛋白质-蛋白质相互作用(PPI)网络与机器学习技术的结合,有助于将S100A12识别为一种潜在的早期诊断通用生物标志物和这三种疾病的治疗靶点。最终,对S100A12的验证表明,其结果与我们的实验结果一致,证实了其作为生物标志物的可靠性。此外,它对这三种疾病均表现出良好的诊断性能。
我们采用生物信息学方法和机器学习技术,研究了COVID-19、AMI和AIS的共同诊断生物标志物和免疫浸润特征。功能和途径分析表明,co-DEGs主要富集在与白细胞和中性粒细胞相关的免疫炎症反应中。通过两种机器学习方法、PPI网络以及后续的验证和评估,我们确定S100A12是一种潜在的与免疫反应相关的通用治疗靶点和生物标志物,可能影响这三种疾病。